Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb)

NeuroToxicology

Volumn 39, Issue , 2013, Pages 95-101

  Bihaqi, Syed Waseem ^a   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Aging; Alzheimer's disease; Cdk5; Hyperphosphorylation; Lead; Tau protein

Indexed keywords

CYCLIN DEPENDENT KINASE 5; LEAD; MESSENGER RNA; PROTEIN P25; PROTEIN P35; PROTEIN TYROSINE PHOSPHATASE; TAU PROTEIN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPOSURE; FEMALE; FRONTAL CORTEX; GENE EXPRESSION; IMMUNOREACTIVITY; MACACA FASCICULARIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; TAUOPATHY;

AGING; ALZHEIMER'S DISEASE; CDK5; HYPERPHOSPHORYLATION; LEAD; TAU PROTEIN;

AGING; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; BRAIN; COHORT STUDIES; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; LEAD; LEAD POISONING, NERVOUS SYSTEM; MACACA FASCICULARIS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84884398917     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.07.010     Document Type: Article

References (49)

1. Alashwal H., Dosunmu R., Zawia N.H. Integration of genome-wide expression and methylation data: relevance to aging and Alzheimer's disease. Neurotoxicology 2012, 33:1450-1453.
2. Alonso A.C., Zaidi T., Grundke-Iqbal I., Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:5562-5566.
3. Alonso A.D., Grundke-Iqbal I., Barra H.S., Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997, 94:298-303.
4. Alonso Adel C., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 2004, 279:34873-34881.
5. Barker D.J. Fetal origins of cardiovascular disease. Ann Med 1999, 31(Suppl 1):3-6.
6. Barker D.J., Winter P.D., Osmond C., Margetts B., Simmonds S.J. Weight in infancy and death from ischaemic heart disease. Lancet 1989, 2:577-580.
7. Basha M.R., Murali M., Siddiqi H.K., Ghosal K., Siddiqi O.K., Lashuel H.A., et al. Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J 2005, 19:2083-2084.
8. Basha M.R., Wei W., Bakheet S.A., Benitez N., Siddiqi H.K., Ge Y.W., et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 2005, 25:823-829.
9. Bihaqi S.W., Huang H., Wu J., Zawia N.H. Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer's disease. J Alzheimers Dis 2011, 27:819-833.
10. Bihaqi S.W., Schumacher A., Maloney B., Lahiri D.K., Zawia N.H. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 2012, 9:574-588.
11. Bihaqi S.W., Bahmani A., Subaiea G.M., Zawia N.H. Infantile exposure to lead and late-age cognitive decline: Relevance to AD. Alzheimers Dement 2013.
12. Bijoor A.R., Sudha S., Venkatesh T. Neurochemical and neurobehavioral effects of low lead exposure on the developing brain. Indian J Clin Biochem 2012, 27:147-151.
13. Burns A., Tomlinson B.E., Mann D.M. Observations on the brains of demented old people. J Neurol Sci 1997, 12:785-790.
14. Canfield R.L., Henderson C.R., Cory-Slechta D.A., Cox C., Jusko T.A., Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10μg per deciliter. N Engl J Med 2003, 348:1517-1526.
15. Citron B.A., Dennis J.S., Zeitlin R.S., Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res 2008, 86:2499-2504.
16. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989, 58:453-508.
17. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Aberrant Tsai L.H. Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
18. Dhavan R., Tsai L.H. A decade of CDK5. Nat Rev Mol Cell Biol 2001, 2:749-759.
19. Dosunmu R., Alashwal H., Zawia N.H. Genome-wide expression and methylation profiling in the aged rodent brain due to early-life Pb exposure and its relevance to aging. Mech Ageing Dev 2012, 133:435-443.
20. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegeneration 2009, 4:13.
21. Gluckman P.D., Hanson M.A. Living with the past: evolution, development, and patterns of disease. Science 2004, 305:1733-1736.
22. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 1995, 65:732-738.
23. Heicklen-Klein A., Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 2000, 75:1408-1418.
24. Hu Y.Y., He S.S., Wang X., Duan Q.H., Grundke-Iqbal I., Iqbal K., et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 2002, 160:1269-1278.
25. Iqbal K., Grundke-Iqbal I., Zaidi T., Merz P.A., Wen G.Y., Shaikh S.S., et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 1986, 2:421-426.
26. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010, 7:656-664.
27. Kitazawa M., Cheng D., Laferla F.M. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 2009, 108:1550-1560.
28. Liddell M.B., Lovestone S., Owen M.J. Genetic risk of Alzheimer's disease: advising relatives. Br J Psychiatry 2001, 178:7-11.
29. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005, 22:1942-1950.
30. Liu F., Li B., Tung E.J., Grundke-Iqbal I., Iqbal K., Gong C.X. Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 2007, 26:3429-3436.
31. Lone M.I., He Z.L., Stoffella P.J., Yang X.E. Phytoremediation of heavy metal polluted soils and water: progresses and perspectives. J Zhejiang Univ Sci B 2008, 9:210-220.
32. Mastroeni D., Grover A., Delvaux E., Whiteside C., Coleman P.D., Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 2011, 32:1161-1180.
33. Migliore L., Coppede F. Genetics environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 2009, 667:82-97.
34. Needleman H.L., Schell A., Bellinger D., Leviton A., Allred E.N. The long-term effects of exposure to low doses of lead in childhood An 11-year follow-up report. N Engl J Med 1990, 322:83-88.
35. Niklowitz W.J., Mandybur T.I. Neurofibrillary changes following childhood lead encephalopathy. J Neuropathol Exp Neurol 1975, 34:445-455.
36. Nordberg M., Winblad B., Fratiglioni L., Basun H. Lead concentrations in elderly urban people related to blood pressure and mental performance: results from a population-based study. Am J Ind Med 2000, 38:290-294.
37. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
38. Price D.L., Sisodia S.S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 1994, 45:435-446.
39. Rahman A., Brew B.J., Guillemin G.J. Lead dysregulates serine/threonine protein phosphatases in human neurons. Neurochem Res 2011, 36:195-204.
40. Rice D.C. Lead-induced behavioral impairment on a spatial discrimination reversal task in monkeys exposed during different periods of development. Toxicol Appl Pharmacol 1990, 106:327-333.
41. Rice D.C. Effect of lead during different developmental periods in the monkey on concurrent discrimination performance. Neurotoxicology 1992, 13:583-592.
42. Sengupta A., Grundke-Iqbal I., Iqbal K. Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem Res 2006, 31:1473-1480.
43. Subaiea G.M., Adwan L.I., Ahmed A.H., Stevens K.E., Zawia N.H. Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiol Aging 2013, 34:2421-2430.
44. Tomizawa K., Ohta J., Matsushita M., Moriwaki A., Li S.T., Takei K., et al. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci 2002, 22:2590-2597.
45. Valin A., Cook J.D., Ross S., Saklad C.L., Gill G. Sp1, Sp3 regulate transcription of the cyclin-dependent kinase 5 regulatory subunit 2 (p39) promoter in neuronal cells. Biochim Biophys Acta 2009, 1789:204-211.
46. Voytko M.L. Nonhuman primates as models for aging and Alzheimer's disease. Lab Anim Sci 1998, 48:611-617.
47. Weisskopf M.G., Proctor S.P., Wright R.O., Schwartz J., Spiro A., Sparrow D., et al. Cumulative lead exposure and cognitive performance among elderly men. Epidemiology. 2007, 18:59-66.
48. Wu J., Basha M.R., Brock B., Cox D.P., Cardozo-Pelaez F., McPherson C.A., et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008, 28:3-9.
49. Ziegler E.E., Edwards B.B., Jensen R.L., Mahaffey K.R., Fomon S.J. Absorption and retention of lead by infants. Pediatr Res 1978, 12:29-34.